32
https://pubmed.ncbi.nlm.nih.gov/38116084
Empagliflozin, an SGLT2 inhibitor, protects against palmitate-induced cardiomyocyte injury by improving insulin sensitivity, reducing ER stress, inflammation, and apoptosis, and enhancing fatty acid oxidation via AMPK pathway activation.
